X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BDTX-1535, a fourth-generation, brain-penetrant, covalent EGFR inhibitor, is under investigation in a Phase 1 clinical trial for the treatment of patients with non-small cell lung cancer (NSCLC) or recurrent glioblastoma GBM.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
BDTX-1535, is a EGFR inhibitor (TKI), is under investigation for the treatment of NSCLC harboring intrinsic driver and/or acquired resistance (post-osimertinib) EGFR mutations and glioblastoma multiforme (GBM) with multiple EGFR alterations.
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
The net proceeds will be used for the advancement of the Company’s clinical development pipeline, including potential accelerated approval activities for BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive NSCLC and in glioblastoma multiforme.
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 29, 2023
Details:
The net proceeds will be used for the advancement of the Company’s clinical development pipeline, including potential accelerated approval activities for BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive NSCLC and in glioblastoma multiforme.
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
BDTX-1535 is designed to be a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC).
Lead Product(s): BDTX-1535,Temozolomide
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
BDTX-1535 is designed to be a potent, selective, brain penetrant and irreversible MasterKey inhibitor of EGFR mutations that expressed in glioblastoma multiforme (GBM) and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer (NSCLC).
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Versant Ventures
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Series A Financing December 12, 2022
Details:
BDTX-1535 is an irreversible MasterKey inhibitor of multiple EGFR alterations that utilize similar activated oncogenic EGFR conformations to drive tumor cell growth in GBM and NSCLC.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
The peer-reviewed paper describes computational and functional analyses of HER2 mutations showing that Black Diamond’s MAP discovery engine has the ability to identify and experimentally validate 22 new oncogenic HER2 driver mutations.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
BDTX-1535 is designed as an irreversible, mutant selective, brain-penetrant MasterKey inhibitor of oncogenic mutations of epidermal growth factor receptor expressed in glioblastoma multiforme and intrinsic and acquired resistance EGFR mutations in non-small cell lung cancer.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2022
Details:
BDTX-1535 is designed as potent brain-penetrant inhibitor of a spectrum of EGFR mutations expressed in glioblastoma multiforme and NSCLC. BDTX-1535 showed dose-dependent tumor growth inhibition and achieved complete regression without notable impact on body weight.
Lead Product(s): BDTX-1535
Therapeutic Area: Oncology Product Name: BDTX-1535
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
